INSR and breast carcinoma: We demonstrated that mTORC1 inhibition with RAD001 (everolimus) induces IGF-1R/InsR/IRS-1/IRS-2-dependent activation of PI3K/AKT signaling in ER+ breast cancer cells and human tumors treated ex vivo.